WebSep 1, 2024 · Saphnelo (anifrolumab-fnia) is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy [see Clinical Studies (14)]. … WebThe AstraZeneca Access 360™ program provides personal support and resources to help streamline access and reimbursement for select AstraZeneca medicines, including SAPHNELO. These resources include the Benefits Investigations Report, the Denial Management Guide, and the Peer-to-Peer resource. Explore Access 360.
Saphnelo intravenous: Uses, Side Effects, Interactions ... - WebMD
WebSAPHNELO may affect the way other medicines work, and other medicines may affect how SAPHNELO works. SAPHNELO may cause serious side effects, including: Serious infections: SAPHNELO can lower the ability of your immune system to fight infections. You may be at a higher risk of developing respiratory infections and shingles (herpes zoster ... WebOn August 2, 2024, the U.S. FDA approved anifrolumab, brand name Saphnelo (AstraZeneca Pharmaceuticals LP), for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. port of galveston promo code 2022
FDA Approves Saphnelo: First New Systemic Lupus Erythematosus ... - GoodRx
WebThe most common side effects of SAPHNELO include: upper respiratory infections, infusion reactions, cough, bronchitis, shingles (herpes zoster). These are not all of the possible … WebDailyMed is a website operated by the U.S. National Library of Medicine (NLM) to publish up-to-date and accurate drug labels (also called a "package insert") to health care … WebAug 2, 2024 · The U.S. Food and Drug Administration (FDA) approved Saphnelo to treat adults with moderate to severe systemic lupus erythematosus (SLE ) on August 2, 2024. … port of galveston parking reservation